格隆汇11月27日丨佰金生命科学(01466.HK)公布截至2025年9月30日止六个月之中期业绩。本期间内， 公司拥有人应占综合溢利约为220万港元(截至2024年9月30日止六个月(「2024年上半年」)：亏损620万 港元)。集团于2025年上半年的溢利为250万港元(2024年上半年：亏损190万港元)，乃主要由于可换股债 券的公平值变动收益及毛利的减幅被抵销所致。 ...

Group 1 - The core viewpoint of the article is that Baijin Life Sciences (01466) reported a decrease in revenue but achieved profitability in the latest interim results [1] Group 2 - The company reported revenue of HKD 55.145 million for the six months ending September 30, 2025, representing a year-on-year decrease of 22.22% [1] - The profit attributable to the owners of the company was HKD 2.173 million, marking a turnaround from a loss to profit compared to the previous period [1] - Earnings per share were reported at HKD 0.028 [1] - The turnaround to profitability was primarily due to the fair value changes of convertible bonds, which offset the decline in gross profit [1]

公告称，扭亏为盈主要由于可换股债券的公平值变动收益及毛利的减幅被抵销所致。 智通财经APP讯，佰金生命科学(01466)公布截至2025年9月30日止六个月的中期业绩，收入为5514.5万 港元，同比减少22.22%;公司拥有人应占溢利217.3万港元，同比扭亏为盈;每股盈利0.28港仙。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 Baijin Life Science Holdings Limited 佰金生命科學控股有限公司 （股份代號： 1466） （於開曼群島註冊成立之有限公司） 截 至2025年9月30日 止 六 個 月 之 中 期 業 績 公 告 佰 金 生 命 科 學 控 股 有 限 公 司（「本 公 司」）（前 稱 為 錢 唐 控 股 有 限 公 司）董 事 會（「董 事 會」）欣 然 宣 佈 本 公 司 及 其 附 屬 公 司（統 稱「本 集 團」）截 至2025年 9月30日 止 六 個 月 之 簡 明 綜 合 中 期 業 績，連 同2024年 同 期 之 比 較 數 字。 截 至2025年9月30日 止 六 個 月 | | | ...

格隆汇11月25日丨佰金生命科学(01466.HK)发布公告，集团预期截至2025年9月30日止六个月将录得纯 利约250万港元，而截至2024年9月30日止六个月则录得亏损约为190万港元。集团截至2025年9月30日止 六个月的财务业绩增长主要由于可换股债券公平值变动收益及抵销毛利减少后所致。 相关事件 佰金生命科学(01466.HK)盈喜：预计中期录得纯利250万港元 佰金生命科学(01466.HK)附属北京佰金将 透过认购优环生物股权的方式对优环生物进行投资 ...

智通财经APP讯，佰金生命科学(01466)发布公告，集团预期截至2025年9月30日止六个月将取得纯利约 250万港元，而截至2024年9月30日止六个月则取得亏损约为190万港元。集团截至2025年9月30日止六个 月的财务业绩增长乃主要由于可换股债券公平值变动收益及抵销毛利减少后所致。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （於開曼群島註冊成立之有限公司） （股份代號： 1466） 正面盈利預告 本 公 告 乃 由 佰 金 生 命 科 學 控 股 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）根 據 香 港 聯 合 交 易 所 有 限 公 司（「 聯 交 所 」）證 券 上 市 規 則（「 上 市 規 則 」）第 13.09 (2) (a)條 及 香港 法例 第571 章 證券 及期 貨條 例 第XIVA 部 項下 之內 幕消 息 條文 （ 定義見上市規則 ）而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者， 根據對本集團的未經審核綜合管理賬目作出的初 ...

Core Insights - Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology R&D platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. focuses on circRNA technology platform development and innovative drug development, also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] Group 2: Collaboration Focus Areas - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Baijin's exosome and cell platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, cerebral infarction, Alzheimer's, and Parkinson's diseases [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

Group 1 - Company Baijin Life Sciences (01466) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity acquisition, aiming to establish a leading global circRNA technology research and development platform [1] - The agreement is set to expire on December 31, 2026, and either party can terminate the agreement with a 10-day notice [1] Group 2 - Youhuan is a biopharmaceutical company focused on circRNA technology platform development and innovative drug development, also providing CRO services [2] - Youhuan has successfully obtained U.S. patent authorization for "Circular RNAs and Preparation Methods thereof" and Chinese invention patent authorization for "A Residue-Free Sequence Circular RNA Based on Ribozyme Self-Splicing and Its Preparation Method" [2] - The company is engaged in deep cooperation with large enterprises in the international drug development field and has signed contracts in certain cell application areas with a global multinational company [2] Group 3 - The initial focus of the collaboration will include exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Research will also target circRNA and exosome drug delivery technologies, developing new delivery systems based on exosome and cell platforms [3] - The development of engineered exosome drugs and cell drugs for cardiovascular and tissue repair applications, as well as treatments for neurodegenerative diseases like Alzheimer's and Parkinson's, is also a priority [3] - The collaboration aims to develop precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]

Core Insights - Baijin Life Sciences (01466.HK) has signed a strategic cooperation framework agreement with Youhuan (Suzhou) Biopharmaceutical Technology Co., Ltd. to invest in Youhuan through equity subscription, aiming to establish a leading global circRNA technology research platform and enhance innovation in cell therapy [1][2] Group 1: Company Overview - Youhuan is a dual-driven biopharmaceutical company focusing on circRNA technology platform research and innovative drug development, while also providing CRO services [2] - The company has successfully obtained U.S. patent authorization for its proprietary "Circular RNAs and Preparation Methods" and a Chinese invention patent for a method based on ribozyme self-splicing [2] Group 2: Collaboration Focus - The initial collaboration will prioritize exploring long-acting, stable expression of cytokines and enzymes for treating liver metabolic diseases [3] - Development of circRNA delivery systems using exosome and cell delivery technologies, leveraging Youhuan's platforms [3] - Engineering enhanced exosome and cell drugs for cardiovascular and tissue repair applications, targeting conditions such as myocardial infarction, stroke, and neurodegenerative diseases like Alzheimer's and Parkinson's [3] - Development of precise, efficient, and safe cell reprogramming and differentiation technologies for genetic disease treatment [3]